ME 23ANDME HLDG CO

23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South

23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South

The new African American Genetic Groups feature traces customers' ancestral connections from before the early-to-mid-20th century migrations to more than 200 communities in Southern states

SUNNYVALE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, released a powerful new feature that enables African American customers to trace their roots to over 200 communities of people of African descent in the Southern United States. These communities include those with connections to the Piney Woods region in the dense forests and rolling hills in rural Mississippi; the creoles of the River Parishes and Greater New Orleans who draw on a unique mix of French, Spanish, Native American and African cultures; and the Gullah Geechee of South Carolina and Georgia, among many others.

Many Americans do not realize that before the Great Migration, more than 90 percent of the Black community lived in the South. Then, during the two waves of the Great Migration between 1910 and 1970, roughly six million Black Americans left their homes in primarily rural southern communities, moving north and west in search of economic opportunities, and to escape poverty, repression, and racial violence.

“History is written in our DNA, and it’s important for African Americans to see how their family histories are woven so deeply into the history of the United States,” said Steven Micheletti, Ph.D., 23andMe Senior Scientist, Population Genetics, and lead on the 23andMe African American Genetics Group feature.

“Many African American families whose ancestors fled the South during the Great Migration kept some connection to those communities that they left behind, but over the decades, some families lost those connections. Learning this information could help reconnect families to these communities.”

The new African American Genetic Groups feature offers families and individuals direct links to the places where their ancestors once lived, providing meaningful insights into African American history and heritage within the United States. These communities offer a window into the unique histories, cultures, and traditions passed down over time. The new feature will include shared ancestral locations, a list of common maternal and paternal haplogroups, and additional information to help those tracing their connections to these communities.

23andMe customers will be able to trace connections to the following African American Genetic Groups, among many others:

  • Southern Mississippi Pines African Americans
  • Yazoo River Basin Mississippi African Americans
  • Georgia Coastal Plain African Americans
  • Central Carolinas Piedmont African Americans
  • Central Georgia Piedmont African Americans
  • Central Kentucky African Americans
  • Chesapeake Bay African Americans
  • Savannah River Basin African Americans
  • Lower Alabama African Americans
  • Maryland Western Shore African Americans

(For a full list, please see our ).

For many African American families, tracing their roots can be challenging due to the disruptions caused by the transatlantic slave trade, systemic racism, and displacement during the Great Migration. That massive movement of people transformed the political, cultural, and social landscape in the United States. Families moved along well-worn paths to cities like Chicago, New York, Los Angeles, and Detroit, forever changing the fabric of these urban centers.

Approximately 88 percent of 23andMe customers who self-identify as African American will see connections to at least one of the newly identified African American Genetic Groups. For 23andMe+ Premium™ customers, who have access to more distant connections, this number rises to 95 percent.

About 5 percent of 23andMe customers who identify as white or caucasian and have some African ancestry will also receive matches. Whereas many African Americans are well aware of their mixed ancestry that often includes European ancestry, many people who self-identify as white but have some may not know that same history.

This important new feature is part of a broader effort to improve representation in 23andMe’s product and within its research. For over a decade, 23andMe has taken steps to enhance the diversity of its research dating back to its , and its African .

Most recently, 23andMe collaborated with researchers at the National Institutes of Health and Johns Hopkins University School of Medicine to publish the , linking the trait to increased risk for certain blood clots. In 2023, scientists from 23andMe, Harvard, and the Smithsonian  who labored at a Maryland iron furnace and established genetic connections between them and 40,000 of their living relatives. 23andMe’s new  feature now allows customers to see if they share a connection to these historical individuals.

Contact Information

About 23andMe

23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit investors.23andme.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.



EN
17/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 23ANDME HLDG CO

 PRESS RELEASE

23andMe and Mirador Therapeutics Enter Into Strategic Research Collabo...

23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I)-related diseases, today announced a strategic research collaboration. Under the agreement, Mirador will leverage a...

 PRESS RELEASE

23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

23andMe Reports Second Quarter Fiscal Year 2025 Financial Results SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for the same period in the prior year (see important additional information below).The 23andMe comprehensive Total Health longevity service is now available to all customers, combining wh...

 PRESS RELEASE

23andMe Announces Business Restructuring to Streamline Operations, Red...

23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic programs SUNNYVALE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced a business restructuring to streamline operations and reduce cost...

 PRESS RELEASE

CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

CORRECTION - 23andMe to Report Q2 FY2025 Financial Results SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (Nasdaq: ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter’s results and report on business progres...

 PRESS RELEASE

23andMe to Report Q2 FY2025 Financial Results

23andMe to Report Q2 FY2025 Financial Results SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the second quarter of fiscal year 2025 (FY2025) after the market closes on Tuesday, November 12, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter’s results and report on business progress. The webcast can be accessed on the day of the event at this . A webcast replay will be...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch